The number of warning and untitled letters has dropped in recent years. Only four letters have been sent so far this year, compared to 28 in 2012.
Excedrin's #DebateHeadache was inspired by complaints the brand noticed during the first presidential debate in September.
Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market
Digitas Health LifeBrands used Snapchat and Twitter to drive immunodeficiency patient Seth's story. The effort garnered 188 million impressions for #wearyellowforseth.
Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines
The agency's ambitions were fueled in part by external criticism. The barbs that stung most sharply were ones suggesting a certain indifference on the FDA's part.
A study of the social media activity of pharmaceutical firms finds that Lilly is the most active, but Novo Nordisk and Boehringer Ingelheim have better engagement.
For years the social network has been telling advertisers they must pay to magnify their exposure, but most continue to resist.
The anti-tobacco movement Truth is hitting young people in their pocketbooks with a new spot called "Squadless."
Twitter's health team offers advice on how pharma and healthcare companies can more effectively utilize 140 characters.
The unbranded campaign won the top prize at the 2015 Lions Health festival in Cannes.
Healthcare and tech executives say it's possible for pharma to engage, use humor, and have fun on social media.
The Facebook for doctors launches Pages, allowing healthcare companies to establish a presence on Sermo and engage with physicians.
Technology executives discussed how pharma companies can leverage social media to better engage with patients online.
Social is a big deal in healthcare. Marketers can use it to create positive chatter and win greater awareness, recognition, and credibility among target audiences.
Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.
Part of LinkedIn's appeal lies in the high level of engagement of its members and the potential for precise targeting of content and talent searches.
Social listening can help all along the value chain—from research and discovery to developing marketing plans and strategy.
The company "embraces" adverse-event reporting and knows not to expect monetary ROI from unbranded initiatives, says its US-based social media lead.
Many patients allow doctors to access their social-media accounts; Turing will reportedly lower the price of Daraprim by 10%; WebMD reports boost in traffic
Work hard to get everyone in your company to understand what you can learn from social listening—you'll know you're successful when inquisitive minds throughout the company start asking you the question, "Can we find out what patients are saying about this brand online?"
An analysis conducted by J&J executives found that 58% of FDA warning letters and untitled letters over the last two years omitted risk information.
The drugmaker launched its first YouTube channel as it kicked off the campaign.
Stakeholder activists, social media and an increasingly global market are three defining issues for companies operating in the 21st century.
Pharma has hidden behind the ability to turn commenting off on Facebook pages, allowing marketers to use the channel much as they would a typical web page.
Kim Kardashian posts corrective information on Instagram and Twitter; DPP-4 inhibitors are linked to joint pain; doctors question off-label prescriptions of PCSK9 inhibitors
While social media can be a tool for pharma to help educate the public, it has also become a forum for the public to express their views about pharma, and it's not always flattering, as evidenced by the recent antivaccine movement.
The FDA said Kim Kardashian West's promotion of morning-sickness pill Diclegis misbranded the product by understating its risks.
From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.
The pharma business needs to take engagement far more seriously than it has in the past. At the same time, there are signs that the industry is finally acting with more urgency and even transparency.
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy